Recent Findings in JAMA Network Open Suggest Potential Benefits of Comprehensive Germline Genetic Testing for Mesothelioma Patients. While asbestos exposure remains a primary risk factor for mesothelioma, a segment of patients also carry harmful genetic variations that amplify susceptibility to solid tumors. Researchers, led by a team from the University of Chicago, investigated 161 mesothelioma patients who underwent both tumor-specific and germline next-generation sequencing. Results indicated that 16% of patients bore pathogenic or potentially pathogenic genetic variations, predominantly within a gene associated with hereditary cancer syndromes. These genetic alterations were detected at a similar frequency to other tumor types like metastatic prostate cancer, epithelial ovarian cancer, and exocrine pancreatic cancer, all of which recommend universal germline genetic testing. Given the comparable prevalence of P/LP germline variants in mesothelioma patients to other cancers where universal genetic testing is established, the researchers advocate contemplating universal germline screening as part of forthcoming mesothelioma treatment guidelines.
We are your go-to resource for all things mesothelioma. Learn about types, symptoms, diagnosis, treatment options, and prevention of this rare cancer linked to asbestos exposure. Connect with support groups, access patient resources, and join us in the fight against mesothelioma. Explore now.
Comments
Post a Comment